China Pharma Holdings was given the go-ahead by the SFDA to begin clinical trials of a novel antibiotic combination formula. China Pharma describes the new product as a third generation Cephalosporin antibiotic combined with a bacterial-enzyme inhibitor. Its clinical trial will begin in November. The complete run of clinical trials will take two years, according to the company.  More details...

Stock Symbol: (OTCBB: CPHI)